Citations (36)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Gift D Pule, Shaheen Mowla, Nicolas Novitzky, Charles S Wiysonge & Ambroise Wonkam. (2015) A systematic review of known mechanisms of hydroxyurea-induced fetal hemoglobin for treatment of sickle cell disease. Expert Review of Hematology 8:5, pages 669-679.
Read now
Read now
Masoud Nahavandi, Fatemeh Tavakkoli, Richard M. Millis, Melville Q.-Wyche, Muhammad J. Habib & Nasrin Tavakoli. (2006) Effects of hydroxyurea and L-arginine on the production of nitric oxide metabolites in cultures of normal and sickle erythrocytes. Hematology 11:4, pages 291-294.
Read now
Read now
Fatemeh Tavakkoli, Masoud Nahavandi, Melville Q Wyche & Elliott Perlin. (2004) Plasma Levels of TNF- in Sickle Cell Patients Receiving Hydroxyurea. Hematology 9:1, pages 61-64.
Read now
Read now
KARL A. NATH, ZVONIMIR S. KATUSIC & MARK T. GLADWIN. (2004) The Perfusion Paradox and Vascular Instability in Sickle Cell Disease. Microcirculation 11:2, pages 179-193.
Read now
Read now
Melville Q. Wyche, Elliott Perlin, Richard M. Millis, Masoud Nahavandi & Fatemeh Tavakkoli. (2003) Arterialization of Venous Blood for Differentiation of Sickle Cell Subjects in Vaso-occlusive Crisis. Hematology 8:6, pages 421-428.
Read now
Read now
Articles from other publishers (31)
Crystal M. Taylor, Malgorzata Kasztan, Randee Sedaka, Patrick A. Molina, Luke S. Dunaway, Jennifer S. Pollock & David M. Pollock. (2021) Hydroxyurea improves nitric oxide bioavailability in humanized sickle cell mice. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 320:5, pages R630-R640.
Crossref
Crossref
Elie Nader, Marijke Grau, Romain Fort, Bianca Collins, Giovanna Cannas, Alexandra Gauthier, Katja Walpurgis, Cyril Martin, Wilhelm Bloch, Solène Poutrel, Arnaud Hot, Céline Renoux, Mario Thevis, Philippe Joly, Marc Romana, Nicolas Guillot & Philippe Connes. (2018) Hydroxyurea therapy modulates sickle cell anemia red blood cell physiology: Impact on RBC deformability, oxidative stress, nitrite levels and nitric oxide synthase signalling pathway. Nitric Oxide 81, pages 28-35.
Crossref
Crossref
Sargam Kapoor, Jane A. Little & Lydia H. Pecker. (2018) Advances in the Treatment of Sickle Cell Disease. Mayo Clinic Proceedings 93:12, pages 1810-1824.
Crossref
Crossref
Emily Riehm Meier. (2018) Treatment Options for Sickle Cell Disease. Pediatric Clinics of North America 65:3, pages 427-443.
Crossref
Crossref
Bharatsing Rathod D, Sunil Bhaisare D & Keyur Kishor Dave. (2017) CORRELATION OF HAEMOLYTIC FACTORS AND HYDROXYUREA TREATMENT IN SICKLE CELL ANAEMIA WITH PULMONARY HYPERTENSION. Journal of Evolution of Medical and Dental Sciences 6:60, pages 4398-4402.
Crossref
Crossref
Emily Riehm Meier & Angeli Rampersad. (2016) Pediatric sickle cell disease: past successes and future challenges. Pediatric Research 81:1-2, pages 249-258.
Crossref
Crossref
Dachuan ZhangChunliang XuDeepa Manwani & Paul S. Frenette. (2016) Neutrophils, platelets, and inflammatory pathways at the nexus of sickle cell disease pathophysiology. Blood 127:7, pages 801-809.
Crossref
Crossref
Lydia H. Pecker & Hans C. Ackerman. 2016. Sickle Cell Anemia. Sickle Cell Anemia
129
175
.
Richard Kobina Dadzie Ephraim, Derick Nii Mensah Osakunor, Obed Cudjoe, Enos Amoako Oduro, Lyudmila Asante-Asamani, Juliana Mitchell, Hope Agbodzakey & Prince Adoba. (2015) Chronic kidney disease is common in sickle cell disease: a cross-sectional study in the Tema Metropolis, Ghana. BMC Nephrology 16:1.
Crossref
Crossref
Andrew Barazia, Jing Li, Kyungho Kim, Namrata Shabrani & Jaehyung Cho. (2015) Hydroxyurea with AKT2 inhibition decreases vaso-occlusive events in sickle cell disease mice. Blood 126:22, pages 2511-2517.
Crossref
Crossref
Maria Pikilidou, Maria Yavropoulou, Maria Antoniou, Eleftherios Papakonstantinou, Despoina Pantelidou, Panagiota Chalkia, Peter Nilsson, John Yovos & Pantelis Zebekakis. (2015) Arterial Stiffness and Peripheral and Central Blood Pressure in Patients With Sickle Cell Disease. The Journal of Clinical Hypertension 17:9, pages 726-731.
Crossref
Crossref
Camila Bononi AlmeidaLucas Eduardo Botelho Souza, Flavia Costa LeonardoFabio Trindade Maranhão Costa, Claudio C. Werneck, Dimas Tadeu CovasFernando Ferreira CostaNicola Conran. (2015) Acute hemolytic vascular inflammatory processes are prevented by nitric oxide replacement or a single dose of hydroxyurea. Blood 126:6, pages 711-720.
Crossref
Crossref
Sarah Y. Lockwood, Jayda L. Erkal & Dana M. Spence. (2014) Endothelium-derived nitric oxide production is increased by ATP released from red blood cells incubated with hydroxyurea. Nitric Oxide 38, pages 1-7.
Crossref
Crossref
Katherine C. Wood, Lewis L. Hsu & Mark T. Gladwin. (2008) Sickle cell disease vasculopathy: A state of nitric oxide resistance. Free Radical Biology and Medicine 44:8, pages 1506-1528.
Crossref
Crossref
Antonio Guasch, Jose Navarrete, Kaleed Nass & Carlos F. Zayas. (2006) Glomerular Involvement in Adults with Sickle Cell Hemoglobinopathies: Prevalence and Clinical Correlates of Progressive Renal Failure. Journal of the American Society of Nephrology 17:8, pages 2228-2235.
Crossref
Crossref
Hutchinson James, Masoud Nahavandi, Melville Q. Wyche & Robert E. Taylor. (2006) Quantitative analysis of trimethylsilyl derivative of hydroxyurea in plasma by gas chromatography–mass spectrometry. Journal of Chromatography B 831:1-2, pages 42-47.
Crossref
Crossref
Claudia R Morris. (2006) New Strategies for the Treatment of Pulmonary Hypertension in Sickle Cell Disease. Treatments in Respiratory Medicine 5:1, pages 31-45.
Crossref
Crossref
Fatemeh Tavakkoli, Masoud Nahavandi, Melville Q. Wyche & Oswaldo Castro. (2005) Effects of hydroxyurea treatment on cerebral oxygenation in adult patients with sickle cell disease: an open-label pilot study. Clinical Therapeutics 27:7, pages 1083-1088.
Crossref
Crossref
Byung-Jo Kim, Kun-Woo Park, Seong-Beom Koh, Han-Kyum Kim, Hye Lim Jung, Min-Kyu Park & Dae-Hie Lee. (2005) Stroke induced by splenectomy in hemoglobin Madrid: autopsy clues to the underlying mechanism. Blood Coagulation & Fibrinolysis 16:2, pages 141-144.
Crossref
Crossref
Claire N. Harrison. (2005) Platelets and Thrombosis in Myeloproliferative Diseases. Hematology 2005:1, pages 409-415.
Crossref
Crossref
Nicola Conran, Camila Oresco‐Santos, Heloisa C. Acosta, André Fattori, Sara T. O. Saad & Fernando F. Costa. (2004) Increased soluble guanylate cyclase activity in the red blood cells of sickle cell patients. British Journal of Haematology 124:4, pages 547-554.
Crossref
Crossref
Claudia R. Morris, Elliott P. Vichinsky, Jane van Warmerdam, Lorenzo Machado, Diane Kepka-Lenhart, Sidney M. Morris,Jr.Jr. & Frans A. Kuypers. (2003) Hydroxyurea and Arginine Therapy: Impact on Nitric Oxide Production in Sickle Cell Disease. Journal of Pediatric Hematology/Oncology 25:8, pages 629-634.
Crossref
Crossref
Claudia R. Morris, Sidney M. MorrisJr.Jr., Ward Hagar, Jane van Warmerdam, Susan Claster, Diane Kepka-Lenhart, Lorenzo Machado, Frans A. Kuypers & Elliott P. Vichinsky. (2003) Arginine Therapy. American Journal of Respiratory and Critical Care Medicine 168:1, pages 63-69.
Crossref
Crossref
Virginia L. Lockamy, Jinming Huang, Howard Shields, Samir K. Ballas, S.Bruce King & Daniel B. Kim-Shapiro. (2003) Urease enhances the formation of iron nitrosyl hemoglobin in the presence of hydroxyurea. Biochimica et Biophysica Acta (BBA) - General Subjects 1622:2, pages 109-116.
Crossref
Crossref
Christopher D. Reiter & Mark T. Gladwin. (2003) An emerging role for nitric oxide in sickle cell disease vascular homeostasis and therapy. Current Opinion in Hematology 10:2, pages 99-107.
Crossref
Crossref
S. Bruce King. (2003) A role for nitric oxide in hydroxyurea-mediated fetal hemoglobin induction. Journal of Clinical Investigation 111:2, pages 171-172.
Crossref
Crossref
Vladan P. Cokic, Reginald D. Smith, Bojana B. Beleslin-Cokic, Joyce M. Njoroge, Jeffery L. Miller, Mark T. Gladwin & Alan N. Schechter. (2003) Hydroxyurea induces fetal hemoglobin by the nitric oxide–dependent activation of soluble guanylyl cyclase. Journal of Clinical Investigation 111:2, pages 231-239.
Crossref
Crossref
Christina Halsey & Irene A. G. Roberts. (2003) The role of hydroxyurea in sickle cell disease. British Journal of Haematology 120:2, pages 177-186.
Crossref
Crossref
M Brun, S Bourdoulous, P O Couraud, J Elion, R Krishnamoorthy & C Lapoumeroulie. (2003) Hydroxyurea downregulates endothelin-1 gene expression and upregulates ICAM-1 gene expression in cultured human endothelial cells. The Pharmacogenomics Journal 3:4, pages 215-226.
Crossref
Crossref
Masoud Nahavandi, Fatemeh Tavakkoli, Melville Q. Wyche, Elliott Perlin, William P. Winter & Oswaldo Castro. (2002) Nitric oxide and cyclic GMP levels in sickle cell patients receiving hydroxyurea. British Journal of Haematology 119:3, pages 855-857.
Crossref
Crossref
Mark T. Gladwin, James H. Shelhamer, Frederick P. Ognibene, Margaret E. Pease-Fye, James S. Nichols, Beth Link, Daksesh B. Patel, Marcin A. Jankowski, Lewis K. Pannell, Alan N. Schechter & Griffin P. Rodgers. (2002) Nitric oxide donor properties of hydroxyurea in patients with sickle cell disease. British Journal of Haematology 116:2, pages 436-444.
Crossref
Crossref